Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Show more

200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada

Biotechnology
Healthcare
Start AI Chat

Market Cap

3.301B

52 Wk Range

$26.74 - $46.60

Previous Close

$42.72

Open

$43.35

Volume

942,546

Day Range

$43.14 - $44.82

Enterprise Value

2.544B

Cash

462.3M

Avg Qtr Burn

-71.75M

Insider Ownership

0.14%

Institutional Own.

-

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XEN1101 Details
Epilepsy, Seizures, Primary Generalized Tonic Clonic Seizures

Phase 3

Data readout

Phase 3

Data readout

Azetukalner (XEN1101) (Kv7 Opener) Details
Mental Health, Bipolar Depression

Phase 3

Update

XEN1101 Details
Mental health, Major depressive disorder

Phase 3

Update

Azetukalner (XEN1101) Details
Epilepsy, Focal Onset Seizures

Phase 2b

Update

XEN901/NBI-921352 Details
Epilepsy, Focal Onset Seizures

Phase 2

Update

Phase 1

Update

Phase 1

Update

Failed

Discontinued

Failed

Discontinued